Shanghai Haohai Biological Technology Co (SHSE:688366) Cash-to-Debt : 12.81 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Haohai Biological Technology Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Shanghai Haohai Biological Technology Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 12.81.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Shanghai Haohai Biological Technology Co could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Shanghai Haohai Biological Technology Co's Cash-to-Debt or its related term are showing as below:

SHSE:688366' s Cash-to-Debt Range Over the Past 10 Years
Min: 6.74 Med: 37.28 Max: No Debt
Current: 12.81

During the past 10 years, Shanghai Haohai Biological Technology Co's highest Cash to Debt Ratio was No Debt. The lowest was 6.74. And the median was 37.28.

SHSE:688366's Cash-to-Debt is ranked better than
59.2% of 1527 companies
in the Biotechnology industry
Industry Median: 6.23 vs SHSE:688366: 12.81

Shanghai Haohai Biological Technology Co Cash-to-Debt Historical Data

The historical data trend for Shanghai Haohai Biological Technology Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Shanghai Haohai Biological Technology Co Cash-to-Debt Chart

Shanghai Haohai Biological Technology Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

64.82

28.75

27.55

21.49

6.74

Shanghai Haohai Biological Technology Co Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															N/A	12.27	9.71	6.74	12.81

Competitive Comparison of Shanghai Haohai Biological Technology Co's Cash-to-Debt

For the Biotechnology subindustry, Shanghai Haohai Biological Technology Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Haohai Biological Technology Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Haohai Biological Technology Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Shanghai Haohai Biological Technology Co's Cash-to-Debt falls into.

Shanghai Haohai Biological Technology Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Shanghai Haohai Biological Technology Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2751.082	/	(216.625	+	191.324)
	=	6.74

Shanghai Haohai Biological Technology Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2726.67	/	(10	+	202.822)
	=	12.81

Shanghai Haohai Biological Technology Co (SHSE:688366) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Shanghai Haohai Biological Technology Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Shanghai Haohai Biological Technology Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Haohai Biological Technology Co (SHSE:688366) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Haohai Biological Technology Co Ltd (SHSE:688366) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

06826:Hong Kong

Address

No. 1386 Hongqiao Road, 23rd Floor, WenGuang Plaza, Changning District, Shanghai, CHN

Website

https://www.3healthcare.com

Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. It is also engaged in the research and development of biological engineering, pharmaceutical and ophthalmology products, and the provision of related services. Its products are categorized into four types comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China which is the key revenue driver, the United States, the United Kingdom, and other countries.

Executives

Du Peng	Core technical personnel
Liu Lu	Core technical personnel
Ren Cai Xia	senior management
Wang Wen Bin	Senior management, core technical personnel
Tang Min Jie	Directors, senior managers
Wu Jian Ying	Directors, senior managers
Jiang Li Xia	Core technical personnel
	Core technical personnel
Hou Yong Tai	Director, core technical staff

Shanghai Haohai Biological Technology Co (SHSE:688366) Headlines

No Headlines